Why the study?
Right ventricular dysfunction remains a major determinant of prognosis in pulmonary hypertension regardless of etiology, prompting a need to evaluate the role of PET imaging in assessing disease severity and clinical outcomes.
Does PET imaging evaluate disease severity and predict clinical outcomes in patients with pulmonary hypertension?
Does PET imaging evaluate disease severity and predict clinical outcomes in patients with pulmonary hypertension?
PET imaging, particularly using [18F]FDG and SUV RV/LV ratios, is a valuable noninvasive tool for assessing RV function and prognosis in pulmonary hypertension, though standardization is needed.
Supports PET SUV RV/LV for PH prognostication; confirms associations across studies but standardization and validation trials remain essential.
Aim Pulmonary Hypertension (PH) is a complex pathophysiological condition associated with high morbidity and mortality. Regardless of etiology, Right Ventricular (RV) dysfunction remains a major determinant of prognosis. This integrative review summarizes the current evidence on the role of Positron Emission Tomography (PET) imaging in evaluating disease severity and exploring associations with clinical outcomes in PH, emphasizing how different tracers capture the biological processes underlying RV dysfunction. Materials and methods A systematic literature search was performed using PubMed, EMBASE, Scopus, and Web of Science, identifying 35 eligible studies. The review discusses PET tracers, technical aspects of image processing and quantification techniques, and metrics correlated with physiological measures, highlighting their diagnostic and prognostic implications. Results PET tracers used for RV assessment in PH include [ 13 N]NH 3 , [ 11 C]acetate, [¹⁸F]FDG, [ 68 Ga]FAPI, and [¹⁸F]LMI1195, with [¹⁸F]FDG being the most widely employed. Quantification predominantly relies on the standardized uptake value (SUV) and kinetic modeling parameters. Common metrics include SUV mean , SUV max , and the RV/Left Ventricle (LV) SUV ratio (SUV RV/LV ), which improves inter-patient comparability. However, variability in acquisition and analysis methods limits cross-study comparability. Some studies report SUV RV/LV thresholds above 1.0 as predictors of adverse outcomes, including increased mortality, greater RV dysfunction, and disease severity. Conclusion PET imaging represents a valuable, noninvasive modality for evaluating RV function and prognosis in PH. Elevated SUV and SUV RV/LV have been reported to be associated with adverse outcomes in several studies. However, methodological heterogeneity limits cross-study comparability. Future studies should aim to standardize acquisition and quantification protocols and include larger prospective studies.
No takes yet. Share an insight, caveat, or question.
Pinto et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: